Login Register Cart 0
Generic placeholder image

Reviews on Recent Clinical Trials

Editor-in-Chief

ISSN (Print): 1574-8871
ISSN (Online): 1876-1038

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Patient-reported Outcome Measures in Perianal Fistulizing Crohn’s Disease

Author(s): Natália Sousa Freitas Queiroz*, Karoline Soares Garcia, Eron Fabio Miranda and Paulo Gustavo Kotze

Volume 17, Issue 3, 2022

Published on: 02 August, 2022

Page: [143 - 155] Pages: 13

DOI: 10.2174/1574887117666220425125424

Price: $65

Abstract

Perianal fistulizing Crohn’s disease (PFCD) is a disabling complication of Crohn’s disease (CD) that can significantly impact the patients’ quality of life (QoL) and often requires multidisciplinary care. Clinical trials assessing the efficacy of medical and surgical interventions for fistulas usually evaluate outcomes such as the closure of fistula tracts or radiologic healing. However, these traditional outcome assessments fail to capture the impact of the disease from patients’ perspectives. In this context, regulatory authorities have increasingly encouraged the inclusion of validated patient-reported outcomes (PRO) that assess disease activity and reveal how a patient functions and feels. This recent trend toward patient-centered care aims to ensure that improvements in efficacy outcomes are accompanied by meaningful benefits to patients. The aim of this review is to discuss currently available PRO measures (PROMS) for the assessment of PFCD to provide physicians with appropriate tools aiming to optimize patient care and disseminate the use of these instruments in clinical practice.

Keywords: Crohn’s disease, fistula, patient-reported outcome measures, quality of life, magnetic resonance imaging, rectal fistula.

Next »
[1]
Kotze PG, Shen B, Lightner A, et al. Modern management of perianal fistulas in Crohn’s disease: Future directions. Gut 2018; 67(6): 1181-94.
[http://dx.doi.org/10.1136/gutjnl-2017-314918] [PMID: 29331943]
[2]
Panés J, Rimola J. Perianal fistulizing Crohn’s disease: Pathogenesis, diagnosis and therapy. Nat Rev Gastroenterol Hepatol 2017; 14(11): 652-64.
[http://dx.doi.org/10.1038/nrgastro.2017.104] [PMID: 28790453]
[3]
Parks AG, Gordon PH, Hardcastle JD. A classification of fistula-inano. Br J Surg 1976; 63(1): 1-12.
[http://dx.doi.org/10.1002/bjs.1800630102] [PMID: 1267867]
[4]
American Gastroen Terological Association medical position statement: Perianal crohn’s disease. Gastroenterology 2003; 125(5): 1503-7.
[http://dx.doi.org/10.1016/j.gastro.2003.08.024] [PMID: 14598267]
[5]
Graf W, Andersson M, Åkerlund JE, Börjesson L. Long-term outcome after surgery for Crohn’s anal fistula. Colorectal Dis 2016; 18(1): 80-5.
[http://dx.doi.org/10.1111/codi.13106] [PMID: 26338142]
[6]
Sahnan K, Tozer PJ, Adegbola SO, et al. Developing a core outcome set for fistulising perianal Crohn’s disease. Gut 2019; 68(2): 226-38.
[http://dx.doi.org/10.1136/gutjnl-2017-315503] [PMID: 29437911]
[7]
Bojic D, Bodger K, Travis S. Patient reported outcome measures (PROMs) in inflammatory bowel disease: New data. J Crohn’s Colitis 2017; 11 (Suppl. 2): S576-85.
[http://dx.doi.org/10.1093/ecco-jcc/jjw187] [PMID: 27797917]
[8]
Williet N, Sandborn WJ, Peyrin-Biroulet L. Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease. Clin Gastroenterol Hepatol 2014; 12(8): 1246-56.e6.
[http://dx.doi.org/10.1016/j.cgh.2014.02.016]
[9]
Cohen ER, Melmed GY. Making a case for patient-reported outcomes in clinical inflammatory bowel disease practice. Clin Gastroenterol Hepatol 2018; 16(5): 603-7.
[http://dx.doi.org/10.1016/j.cgh.2017.12.027] [PMID: 29678238]
[10]
Rothrock NE, Kaiser KA, Cella D. Developing a valid patient-reported outcome measure. Clin Pharmacol Ther 2011; 90(5): 737-42.
[http://dx.doi.org/10.1038/clpt.2011.195] [PMID: 21975345]
[11]
Alrubaiy L, Hutchings HA, Williams JG. Assessing patient reported outcome measures: A practical guide for gastroenterologists. United European Gastroenterol J 2014; 2(6): 463-70.
[http://dx.doi.org/10.1177/2050640614558345] [PMID: 25452841]
[12]
Guidance for industry. Patient-reported outcome measures: Use in medical product development to support labeling claims: Draft guidance. Health Qual Life Outcomes 2006; 4(1): 79.
[http://dx.doi.org/10.1186/1477-7525-4-79]
[13]
Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: An update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): Determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology 2021; 160(5): 1570-83.
[http://dx.doi.org/10.1053/j.gastro.2020.12.031] [PMID: 33359090]
[14]
Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn’s disease activity index. national cooperative Crohn’s disease study. Gastroenterology 1976; 70(3): 439-44.
[http://dx.doi.org/10.1016/S0016-5085(76)80163-1] [PMID: 1248701]
[15]
Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn’s disease. Gastroenterology 2002; 122(2): 512-30.
[http://dx.doi.org/10.1053/gast.2002.31072] [PMID: 11832465]
[16]
Irvine EJ. Usual therapy improves perianal Crohn’s disease as measured by a new disease activity index. McMaster IBD Study Group. J Clin Gastroenterol 1995; 20(1): 27-32.
[http://dx.doi.org/10.1097/00004836-199501000-00008] [PMID: 7884173]
[17]
Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 1999; 340(18): 1398-405.
[http://dx.doi.org/10.1056/NEJM199905063401804] [PMID: 10228190]
[18]
Lee T, Yong E, Ding NS. Radiological outcomes in perianal fistulizing Crohn’s disease: A systematic review and meta-analysis. JGH Open 2019; 4(3): 340-4.
[http://dx.doi.org/10.1002/jgh3.12295] [PMID: 32514434]
[19]
Van Assche G, Vanbeckevoort D, Bielen D, et al. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn’s disease. Am J Gastroenterol 2003; 98(2): 332-9.
[http://dx.doi.org/10.1016/S0002-9270(02)05909-9] [PMID: 12591051]
[20]
Porter ME. What is value in health care? N Engl J Med 2010; 363(26): 2477-81.
[http://dx.doi.org/10.1056/NEJMp1011024] [PMID: 21142528]
[21]
Losco A, Viganò C, Conte D, Cesana BM, Basilisco G. Assessing the activity of perianal Crohn’s disease: Comparison of clinical indices and computer-assisted anal ultrasound. Inflamm Bowel Dis 2009; 15(5): 742-9.
[http://dx.doi.org/10.1002/ibd.20826] [PMID: 19023861]
[22]
Adegbola SO, et al. Development and initial psychometric validation of a patient-reported outcome measure for Crohn’s perianal fistula: The Crohn’s Anal Fistula Quality of Life (CAF-QoL) scale. Gut 2020; 1-8.
[http://dx.doi.org/10.1136/gutjnl-2019-320553] [PMID: 33272978]
[23]
European Medicines Agency. Guideline on the development of new medicinal products for the treatment of Crohn’s disease 2017. Available from: www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/07/WC500211430.pdf
[24]
U.S. Department of Health and Human Services - Food and Drug Administration. Ulcerative colitis: Clinical trial endpoints guidance for industry 2016. Available from: https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM5
[25]
Echarri A, Castro J, Barreiro M, Carpio D, Pereira S, Lorenzo A. Evaluation of adalimumab therapy in multidisciplinary strategy for perianal Crohn’s disease patients with infliximab failure. J Crohn’s Colitis 2010; 4(6): 654-60.
[http://dx.doi.org/10.1016/j.crohns.2010.07.012] [PMID: 21122576]
[26]
Gligorijević V, Spasić N, Bojić D, et al. The role of pelvic MRI in assesment of combined surgical and infliximab treatment for perianal Crohn’s disease. Acta Chir Iugosl 2010; 57(3): 89-95.
[http://dx.doi.org/10.2298/ACI1003089G] [PMID: 21066991]
[27]
Grimaud JC, Munoz-Bongrand N, Siproudhis L, et al. Fibrin glue is effective healing perianal fistulas in patients with Crohn’s disease. Gastroenterology 2010; 138(7): 2275-2281, 2281.e1.
[http://dx.doi.org/10.1053/j.gastro.2010.02.013] [PMID: 20178792]
[28]
Horsthuis K, Ziech ML, Bipat S, et al. Evaluation of an MRI-based score of disease activity in perianal fistulizing Crohn’s disease. Clin Imaging 2011; 35(5): 360-5.
[http://dx.doi.org/10.1016/j.clinimag.2010.09.003] [PMID: 21872125]
[29]
Sciaudone G, Di Stazio C, Limongelli P, et al. Treatment of complex perianal fistulas in Crohn disease: Infliximab, surgery or combined approach. Can J Surg 2010; 53(5): 299-304.
[PMID: 20858373]
[30]
Roumeguère P, Bouchard D, Pigot F, et al. Combined approach with infliximab, surgery, and methotrexate in severe fistulizing anoperineal Crohn’s disease: Results from a prospective study. Inflamm Bowel Dis 2011; 17(1): 69-76.
[http://dx.doi.org/10.1002/ibd.21405] [PMID: 20623697]
[31]
Savoye-Collet C, Savoye G, Koning E, Dacher JN, Lerebours E. Fistulizing perianal Crohn’s disease: Contrast-enhanced magnetic resonance imaging assessment at 1 year on maintenance anti-TNF-alpha therapy. Inflamm Bowel Dis 2011; 17(8): 1751-8.
[http://dx.doi.org/10.1002/ibd.21568] [PMID: 21744430]
[32]
Schreiber S, Lawrance IC, Thomsen OØ, Hanauer SB, Bloomfield R, Sandborn WJ. Randomised clinical trial: Certolizumab pegol for fistulas in Crohn’s disease - subgroup results from a placebo-controlled study. Aliment Pharmacol Ther 2011; 33(2): 185-93.
[http://dx.doi.org/10.1111/j.1365-2036.2010.04509.x] [PMID: 21083671]
[33]
Duff S, Sagar PM, Rao M, Dolling S, Sprakes M, Hamlin PJ. Infliximab and surgical treatment of complex anal Crohn’s disease. Colorectal Dis 2012; 14(8): 972-6.
[http://dx.doi.org/10.1111/j.1463-1318.2011.02811.x] [PMID: 21899707]
[34]
Tozer P, Ng SC, Siddiqui MR, et al. Long-term MRI-guided combined anti-TNF-α and thiopurine therapy for Crohn’s perianal fistulas. Inflamm Bowel Dis 2012; 18(10): 1825-34.
[http://dx.doi.org/10.1002/ibd.21940] [PMID: 22223472]
[35]
Antakia R, Shorthouse AJ, Robinson K, Lobo AJ. Combined modality treatment for complex fistulating perianal Crohn’s disease. Colorectal Dis 2013; 15(2): 210-6.
[http://dx.doi.org/10.1111/j.1463-1318.2012.03124.x] [PMID: 22672653]
[36]
Steenholdt C, Brynskov J, Thomsen OØ, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: A randomised, controlled trial. Gut 2014; 63(6): 919-27.
[http://dx.doi.org/10.1136/gutjnl-2013-305279] [PMID: 23878167]
[37]
Panaccione R, Colombel JF, Sandborn WJ, et al. Adalimumab maintains remission of Crohn’s disease after up to 4 years of treatment: Data from CHARM and ADHERE. Aliment Pharmacol Ther 2013; 38(10): 1236-47.
[http://dx.doi.org/10.1111/apt.12499] [PMID: 24134498]
[38]
Dewint P, Hansen BE, Verhey E, et al. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn’s disease: A randomised, double-blind, placebo controlled trial (ADAFI). Gut 2014; 63(2): 292-9.
[http://dx.doi.org/10.1136/gutjnl-2013-304488] [PMID: 23525574]
[39]
Gingold DS, Murrell ZA, Fleshner PR. A prospective evaluation of the ligation of the intersphincteric tract procedure for complex anal fistula in patients with Crohn’s disease. Ann Surg 2014; 260(6): 1057-61.
[http://dx.doi.org/10.1097/SLA.0000000000000479] [PMID: 24374520]
[40]
Hall JF, Bordeianou L, Hyman N, et al. Outcomes after operations for anal fistula: Results of a prospective, multicenter, regional study. Dis Colon Rectum 2014; 57(11): 1304-8.
[http://dx.doi.org/10.1097/DCR.0000000000000216] [PMID: 25285698]
[41]
Reinisch W, Travis S, Hanauer S, Wang H, Shara N, Harris MS. AST-120 (spherical carbon adsorbent) in the treatment of perianal fistulae in mild-to-moderate Crohn’s disease: FHAST-1, a phase 3, multicenter, placebo-controlled study. Inflamm Bowel Dis 2014; 20(5): 872-81.
[http://dx.doi.org/10.1097/MIB.0000000000000031] [PMID: 24694794]
[42]
Göttgens KWA, Smeets RR, Stassen LPS, Beets GL, Pierik M, Breukink SO. Treatment of Crohn’s disease-related high perianal fistulas combining the mucosa advancement flap with platelet-rich plasma: A pilot study. Tech Coloproctol 2015; 19(8): 455-9.
[http://dx.doi.org/10.1007/s10151-015-1311-8] [PMID: 25975971]
[43]
Molendijk I, Bonsing BA, Roelofs H, et al. Allogeneic bone marrow-derived mesenchymal stromal cells promote healing of refractory perianal fistulas in patients with crohn’s disease. Gastroenterology 2015; 149(4): 918-27.e6.
[http://dx.doi.org/10.1053/j.gastro.2015.06.014] [PMID: 26116801]
[44]
Wiese DM, Beaulieu D, Slaughter JC, et al. Use of endoscopic ultrasound to guide adalimumab treatment in perianal Crohn’s disease results in faster fistula healing. Inflamm Bowel Dis 2015; 21(7): 1594-9.
[http://dx.doi.org/10.1097/MIB.0000000000000409] [PMID: 25985245]
[45]
Yang BL, Chen YG, Gu YF, et al. Long-term outcome of infliximab combined with surgery for perianal fistulizing Crohn’s disease. World J Gastroenterol 2015; 21(8): 2475-82.
[http://dx.doi.org/10.3748/wjg.v21.i8.2475] [PMID: 25741157]
[46]
Senéjoux A, Siproudhis L, Abramowitz L, et al. Fistula plug in fistulising ano-perineal crohn’s disease: A randomised controlled trial. J Crohn’s Colitis 2016; 10(2): 141-8.
[http://dx.doi.org/10.1093/ecco-jcc/jjv162] [PMID: 26351393]
[47]
Panés J, García-Olmo D, Van Assche G, et al. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn’s disease: A phase 3 randomised, double-blind controlled trial. Lancet 2016; 388(10051): 1281-90.
[http://dx.doi.org/10.1016/S0140-6736(16)31203-X] [PMID: 27477896]
[48]
Zawadzki A, Johnson LB, Bohe M, Johansson C, Ekelund M, Nielsen OH. An open prospective study evaluating efficacy and safety of a new medical device for rectal application of activated carbon in the treatment of chronic, uncomplicated perianal fistulas. Int J Colorectal Dis 2017; 32(4): 509-12.
[http://dx.doi.org/10.1007/s00384-016-2726-z] [PMID: 27878619]
[49]
Dige A, Hougaard HT, Agnholt J, et al. Efficacy of injection of freshly collected autologous adipose tissue into perianal fistulas in patients with Crohn’s disease. Gastroenterology 2019; 156(8): 2208-2216.e1.
[http://dx.doi.org/10.1053/j.gastro.2019.02.005] [PMID: 30772343]
[50]
Wasmann KA, de Groof EJ, Stellingwerf ME, et al. Treatment of perianal fistulas in crohn’s disease, seton versus anti-tnf versus surgical closure following anti-TNF [PISA]: A randomised controlled trial. J Crohn’s Colitis 2020; 14(8): 1049-56.
[http://dx.doi.org/10.1093/ecco-jcc/jjaa004] [PMID: 31919501]
[51]
Lansdorp CA, Gecse KB, Buskens CJ, et al. Hyperbaric oxygen therapy for the treatment of perianal fistulas in 20 patients with Crohn’s disease. Aliment Pharmacol Ther 2021; 53(5): 587-97.
[http://dx.doi.org/10.1111/apt.16228] [PMID: 33326623]
[52]
Guyatt G, Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989; 96(3): 804-10.
[http://dx.doi.org/10.1016/0016-5085(89)90905-0] [PMID: 2644154]
[53]
Love JR, Irvine EJ, Fedorak RN. Quality of life in inflammatory bowel disease. J Clin Gastroenterol 1992; 14(1): 15-9.
[http://dx.doi.org/10.1097/00004836-199201000-00005] [PMID: 1556402]
[54]
Irvine EJ, Zhou Q, Thompson AK. The short inflammatory bowel disease questionnaire: A quality of life instrument for community physicians managing inflammatory bowel disease. ccrpt investigators. Canadian Crohn’s relapse prevention trial. Am J Gastroenterol 1996; 91(8): 1571-8.
[PMID: 8759664]
[55]
Drossman DA, Leserman J, Li ZM, Mitchell CM, Zagami EA, Patrick DL. The rating form of IBD patient concerns: A new measure of health status. Psychosom Med 1991; 53(6): 701-12.
[http://dx.doi.org/10.1097/00006842-199111000-00010] [PMID: 1758953]
[56]
Ware JEJ Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30(6): 473-83.
[http://dx.doi.org/10.1097/00005650-199206000-00002] [PMID: 1593914]
[57]
Jenkinson C, Stradling J, Petersen S. How should we evaluate health status? a comparison of three methods in patients presenting with obstructive sleep apnoea. Qual Life Res 1998; 7(2): 95-100. Available from http://www.jstor.org/stable/4035318
[58]
Kiran RP, Delaney CP, Senagore AJ, et al. Prospective assessment of Cleveland global quality of life (CGQL) as a novel marker of quality of life and disease activity in Crohn’s disease. Am J Gastroenterol 2003; 98(8): 1783-9.
[http://dx.doi.org/10.1111/j.1572-0241.2003.07592.x] [PMID: 12907333]
[59]
Grunberg SM, Groshen S, Steingass S, Zaretsky S, Meyerowitz B. Comparison of conditional quality of life terminology and visual analogue scale measurements. Qual Life Res 1996; 5(1): 65-72.
[http://dx.doi.org/10.1007/BF00435970] [PMID: 8901368]
[60]
Otley A, Smith C, Nicholas D, et al. The IMPACT questionnaire: A valid measure of health-related quality of life in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2002; 35(4): 557-63.
[http://dx.doi.org/10.1097/00005176-200210000-00018] [PMID: 12394384]
[61]
Varni JW, Seid M, Rode CA. The PedsQL: Measurement model for the pediatric quality of life inventory. Med Care 1999; 37(2): 126-39.
[http://dx.doi.org/10.1097/00005650-199902000-00003] [PMID: 10024117]
[62]
Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics 1993; 4(5): 353-65.
[http://dx.doi.org/10.2165/00019053-199304050-00006] [PMID: 10146874]
[63]
Peyrin-Biroulet L, Cieza A, Sandborn WJ, et al. Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health. Gut 2012; 61(2): 241-7.
[http://dx.doi.org/10.1136/gutjnl-2011-300049] [PMID: 21646246]
[64]
Smets EM, Garssen B, Bonke B, De Haes JC. The Multidimensional fatigue inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 1995; 39(3): 315-25.
[http://dx.doi.org/10.1016/0022-3999(94)00125-O] [PMID: 7636775]
[65]
Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the functional assessment of cancer therapy (FACT) measurement system. J Pain Symptom Manage 1997; 13(2): 63-74.
[http://dx.doi.org/10.1016/S0885-3924(96)00274-6] [PMID: 9095563]
[66]
Reeve BB, Stover AM, Alfano CM, et al. The piper fatigue scale-12 (PFS-12): Psychometric findings and item reduction in a cohort of breast cancer survivors. Breast Cancer Res Treat 2012; 136(1): 9-20.
[http://dx.doi.org/10.1007/s10549-012-2212-4] [PMID: 22933027]
[67]
Fisk JD, Ritvo PG, Ross L, Haase DA, Marrie TJ, Schlech WF. Measuring the functional impact of fatigue: Initial validation of the fatigue impact scale. Clin Infect Dis 1994; 18 (Suppl. 1): S79-83.
[http://dx.doi.org/10.1093/clinids/18.Supplement_1.S79] [PMID: 8148458]
[68]
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67(6): 361-70.
[http://dx.doi.org/10.1111/j.1600-0447.1983.tb09716.x] [PMID: 6880820]
[69]
Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4(6): 561-71.
[http://dx.doi.org/10.1001/archpsyc.1961.01710120031004]
[70]
Zung WW. A self-rating depression scale. Arch Gen Psychiatry 1965; 12(1): 63-70.
[http://dx.doi.org/10.1001/archpsyc.1965.01720310065008] [PMID: 14221692]
[71]
Ferreira R, Murray J. Spielberger’s state-trait anxiety inventory: Measuring anxiety with and without an audience during performance on a stabilometer. Percept Mot Skills 1983; 57(1): 15-8.
[http://dx.doi.org/10.2466/pms.1983.57.1.15] [PMID: 6622152]

Rights & Permissions Print Cite
Article Metrics
4
© 2024 Bentham Science Publishers | Privacy Policy